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A B S T R A C T
Background: End-stage Renal Disease is considered a health problem due to the high prevalence and economic
burden on society and the health system. This study utilizes a cost-utility analysis to evaluate the costs and
outcomes of the Iranian End Stage Renal Disease patients.
Methods: A Markov model-based economic evaluation with a societal perspective, and a lifetime horizon per-
formed to quantify the costs and health-related outcomes in terms of QALY. Direct medical costs obtained from
hospital billing and medical records and direct non-medical costs, and indirect costs derived from interviews
with patients. Three policy options, the hemodialysis, peritoneal dialysis and kidney transplantation were
compared. Most of the Transplants from deceased and rest were from Live Related Donors. One-way and
probabilistic sensitivity analyses were performed to study uncertainty.
Results: Annual average cost of hemodialysis is $13477 cost of peritoneal dialysis is $12865, and cost of
Transplantation is $16450.The Transplantation arm gained 9.43 QALY compared with peritoneal dialysis and
hemodialysis with 6.95 and 6.04 QALY respectively. When Transplantation was compared with peritoneal
dialysis, Incremental Cost-Effectiveness Ratio was $1744 per QALY. ICER value suggests that Transplantation is
cost-effective compared with peritoneal dialysis at a willingness-to-pay threshold of $12,400, and hemodialysis
was dominated.
Conclusion: This study suggests that kidney transplantation is a better option over hemodialysis and peritoneal
dialysis. We conclude that serious efforts ought to be made to foster potential brain-dead donors and altruistic
kidney donation and promote peritoneal dialysis as a superior alternative to hemodialysis for eligible patients.
Introduction
Patients in the End Stage Renal Disease (ESRD) are being treated
with one of the Renal Replacement Therapy (RRT) methods including
hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation
(TX).1 Despite the advances in diagnosis and treatment, the morbidity
and mortality rates of ESRD are high.2 World's population increased
1.1% annually, while the number of patients with ESRD increased by
approximately 6%.3
In parallel with the advances in medicine, kidney transplantation is
one of the most preferred and outstanding treatment methods for ESRD
organ failure, which provides significant benefits in terms of medical,
social and quality of life, costs and reduction in labor loss. But not all
patients can undergo transplantation, and treatment availability is low
for a shortage in donor kidneys. Not all patients are able to undergo
transplantation.4 Estimates on the Global Burden of Disease (GBD) in-
dicated that kidney diseases were responsible for 2,993,000 years of life
lost (YLL) and 38,104,000 disability adjusted life years (DALYs) lost
globally.5
ESRD is one of the most resource-consuming diseases and the in-
creasing frequency of the disease causes more financial resources than
the countries' budget. The high cost of renal replacement therapy (RRT)
presents an economic and ethical dilemma for those responsible for
funding treatment programs for patients with end-stage renal disease
(ESRD).6
According to the 2017 Iran consortium of Dialysis (ICD) report, the
prevalence of ESRD in Iran was 680 per million.7 The main aim of RRT
treatment is to prolong the lifetime of the patients and increase the
quality of their life.8 By the end of 2017 in Iran, 58,000 patients treated
with one of these methods. Hemodialysis was the primary treatment of
the patient in Iran with almost 50% followed by transplantation and
peritoneal dialysis with47 and 3%.7
As for the total cost of the RRT programs in Iran, most of the esti-
mated costs were attributable to HD and TX, and only small percentages
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were because of PD. In the present study, we aimed to determine which
treatment strategies should implement to cover all patients and to as-
sess the costs and health outcomes of the Iranian ESRD patients.
Methods
Research Method and patients descriptions : To compare the
cost-effectiveness of RRT treatment methods, a cost-utility analysis
performed based on the societal perspective and lifetime horizon. Total
of 214 patients recruited from two hospitals (Imam Reza and
Montaserieh) in Mashhad, Iran with 56 patients for PD and 158 for HD.
The inclusion criteria for the study population were ESRD patients
treated with HD or PD, adults (older than 18 years old), had received a
minimum of a three-month therapy with either HD or PD, and had no
contraindications of both modalities (including the incapability of
doing PD at home). Patients who discontinued dialysis therapy within
three months or had combination therapy of both HD and PD excluded
from the study. Most of the Transplants from deceased and rest were
from Live Related Donors. Table 1 gives a description of our study
population.
Model: Four-State Markov model with TreeAge version 2011 soft-
ware used to measure the cost-effectiveness of ESRD. The model states
include HD, PD, TX, and Dead which were determining the states of
ESRD.
According to expert and previous studies4,9–11 these states can
change in such way that HD patients can maintain the same state or go
to other three states. Also this is the case for PD and TX patient's states.
The "Dead" state is absorbed state (Fig. 1). The model used a one-month
cycle length for health state. Lifetime horizon applied in this model.
Using this approach, total lifetime cost and health outcomes amongst
the four policy options compared.
Table 1
Baseline characteristics of patients with ESRD.
Characteristics 41.63(16.38)
Age (years, mean ± SD)
Variables N %
Gender Male 130 60.7
Female 84 39.3
Weight (kg) ≤50 37 17.3
70≥ 50 > 127 59.3
<70 50 23.4
Education Illiterate 23 10.7
High school 88 41.1
Diploma and Associate's degree 77 36
Bachelor's degree and above 26 12.2
Marital status Single 61 28.5
Married 150 70.1
Other 3 1.4
Currently working Yes 59 27.6
No 155 73.4
Income Monthly ≤350 $ 117 54.7
>350 $ 97 45.3
Kt/V, mean (SD) HD 1.45(0.277) –
PD 1.78(0.234) –
Treatment Hemodialysis (HD) 158 73.8
Peritoneal dialysis (PD) 56 26.2




Complementary Insurance Yes 35 16.4
No 179 83.6
Length on dialysis (year), mean (SD) 5.73(4.27) –
Hemoglobin level (g/dl), mean (SD) 10.74(0.8) –
a Social Security Organization (SSO).
b Iran Health Insurance Organization.
c The Military Personnel Insurance Organization (MPIO).
Fig. 1. Schematic diagram of Markov model.
Table 2
The incremental cost-effectiveness ratio (ICER) of options.
Strategy Cost $ Incr Cost Eff Incr Eff ICER Average CE
Peritoneal dialysis 12865 0 6.951 0 0 1850
Hemodialysis
(Dominated)
13477 612 6.049 −0.901 −679 2227
Transplantation 16449 3584 9.430 2.478 1446 1744
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Cost and outcome: Based on societal perspectives direct medical,
direct non-medical and indirect costs included in the analysis. The data
obtained primarily from hospital billing and medical records for a one-
year period. Direct non-medical costs, and indirect costs derived from
interviews with patients using a questionnaire. For direct non-medical
costs, all subjects asked about their travel, food, and accommodation
expenses when they visited hospitals. The direct non-medical costs
pertained to the costs consumed by patients and caregivers while the
indirect costs referred to the income loss of the caregiver in a year.
All costs presented in the year 2017 and discounted at a rate of 6.0%
based on local discount rates12,13 for both costs and outcomes. The
country's threshold is three times of the country's GDP per capita (about
520 million IRR ($12380 ) per QALY) applied in this study. All costs
calculated based on the value of US dollar in 2017.14 Utility values
obtained from the Euro QoL EQ-5D-5L Persian version.15 Patients asked
about their current condition and their condition during states. The
utility data of HD, PD, and TX patients, was 0.72 and 0.75, and 0.82
respectively.
Sensitivity analysis
Considering uncertain parameters of the model including QALY,
initial distribution and the transition probabilities, basic and prob-
abilistic sensitivity analysis carried out using variation range of 20%,
and calculating the costs using the lowest and highest amounts.
A probabilistic sensitivity analysis using a Monte Carlo simulation
conducted in this study. All input parameters assigned a probability
distribution to reflect a possible range of its values. The process re-
peated for 1000 simulations. Each simulation provided one value of
cost-effectiveness. The average value of the probabilistic sensitivity
analysis presented as the ICER value and the cost-effectiveness
acceptability curve.
Results
Costs: Using the societal perspective, the total annual costs of HD
was 566, 055, 000 IRR ($13477 ) cost of PD 540,331,000 IRR ($12865
), and cost of TX was 690,882,000 IRR ($16450 ).
The HD had the highest costs among the three options and showed a
large burden borne by households whereas the PD was the least costly
options. The TX arm gained 9.43 QALY compared with PD and HD with
6.95 and 6.04 QALY respectively.
Base case analysis: The incremental cost-effectiveness ratio (ICER)
of providing the TX was $1744 per QALY gained, which was lower than
the PD with $1850, and HD with $2227 per QALY gained (Table 2). The
cost-effectiveness acceptability curve (Fig. 2) showed the probability of
favoring each option dependent on the level of willingness to pay. At
willingness to pay $12380, TX was the best option.
Sensitivity Analysis: For all uncertain parameters of the model
including QALY, the cost, transition probability, and the initial dis-
tribution based on variation range, the basic sensitivity analysis per-
formed. According to the tornado diagram (Fig. 3), three first para-
meters had the greatest impact on costs. One-way sensitivity analyses
performed on the most-influential variables in the model. The utility of
TX, discount rate for outcomes, utility of HD, and cost of TX noted to be
the most sensitive in the mode. According to the results of the analysis
result was not sensitive to changes of these variables.
A probabilistic sensitivity analysis performed using a Monte Carlo
simulation of 1000 trials and showed that the probability of TX being
more cost-effective at a willingness-to-pay threshold of $12380 (about
520 million IRR) was 54.5%. Fig. 4 depicts these data in the form of an
ICER scatter plot, with the drawn circle representing the 95% CI.
Fig. 2. The cost-effectiveness acceptability curve.
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Fig. 3. The Tornado diagram.
Fig. 4. ICER scatter plot.
A. Moradpour, et al. Clinical Epidemiology and Global Health 8 (2020) 199–204
202
Discussion
Our study showed that kidney transplantation and peritoneal dia-
lysis perform better when compared to hemodialysis and Kidney
Transplantation is more cost-effective, representing a savings of $1477
per patient/y.
The mean annual cost of HD, PD, and TX of Iran was about $13477,
12865, and 16450 respectively that in compare to Turkey ($14652,
14389, and 25390),16 Taiwan ($16643 and 13681, NA),17 Canada
($43816 and 38658, NA),18 and USA ($72486, NA, and 80486),19 so
Iranian ESRD costs had an intermediate level. The HD had the highest
costs among the three options and showed a large burden borne by
households whereas the PD was the least costly options.
The fact that renal transplantation yields more favorable Cost-
Effectiveness than dialysis therapies has been previously demonstrated
in several studies. Our findings are consistent with Howard et al. that
explained clinical practice changes reduce costs, improve patient
quality of life and, in the case of transplantation, increase survival.20
Haller et al. described that live donor renal transplantation is cost ef-
fective and associated with increase in QALYs.4 Yigit et al. found that
kidney transplantation treatment had better cost saving compared to
dialysis and the cost per QALY was lower, and the quality of life and
survival rate of kidney transplantation patients were higher than HD
and PD.16 Some other studies regard that hospital hemodialysis being
the least cost-effective treatment option for patients with terminal
kidney failure.20–22 Peritoneal dialysis and kidney transplantation re-
present more cost-effective therapy strategies.21,23–25
According to the results of the study, Kidney transplantation treat-
ment should be preferred and encouraged when developing health
policies and allocating resources to health care services because of cost-
effectiveness in terms of transplantation, quality of life, patient survival
and cost of treatment. In face of these findings serious efforts ought to
make to foster not only altruistic living kidney donation but also more
effective recruitment of potential brain-dead donors on the one hand
and promote peritoneal dialysis as a superior alternative to hemodia-
lysis for eligible patients on the other.
In summary, in our study, we found that Kidney transplantation was
somewhat more cost-effective than Hemodialysis and Peritoneal dia-
lysis but caution has to be exercised when the results are interpreted.
Choosing between the modalities is a complex decision, where both
medical and non-medical factors attribute selection. In addition serious
efforts ought to be made to foster potential brain-dead donors and al-
truistic kidney donation and promote peritoneal dialysis as a superior
alternative to hemodialysis for eligible patients.
Our study has some limitations. Firstly, we used the calculated
QALY value of other countries because this value has not been calcu-
lated in our country yet, so we used sensitivity analysis for determining
the robustness of the results. Secondly, the data were drawn from a
small group of patients with ESRD and we did not include all the pa-
tients from the country. Finally, our study has the lack of follow up
period, our patients investigated for one year and we need to follow up
patients.
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